These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

343 related articles for article (PubMed ID: 25441671)

  • 1. Matrix metalloproteinase 10 is associated with disease severity and mortality in patients with peripheral arterial disease.
    Martinez-Aguilar E; Gomez-Rodriguez V; Orbe J; Rodriguez JA; Fernández-Alonso L; Roncal C; Páramo JA
    J Vasc Surg; 2015 Feb; 61(2):428-35. PubMed ID: 25441671
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Abnormal circulating levels of metalloprotease 9 and its tissue inhibitor 1 in angiographically proven peripheral arterial disease: relationship to disease severity.
    Tayebjee MH; Tan KT; MacFadyen RJ; Lip GY
    J Intern Med; 2005 Jan; 257(1):110-6. PubMed ID: 15606382
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ten Year Mortality in Different Peripheral Arterial Disease Stages: A Population Based Observational Study on Outcome.
    Sartipy F; Sigvant B; Lundin F; Wahlberg E
    Eur J Vasc Endovasc Surg; 2018 Apr; 55(4):529-536. PubMed ID: 29478910
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevention of ischemic events in patients with peripheral arterial disease design, baseline characteristics and 2-year results an observational study.
    Blinc A; Kozak M; Sabovic M; Božic M; Stegnar M; Poredoš P; Kravos A; Barbic-Žagar B; Pohar Perme M; Stare J;
    Int Angiol; 2011 Dec; 30(6):555-66. PubMed ID: 22233617
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Profile of Circulating Matrix Metalloproteinases in Patients Undergoing Lower Limb Endovascular Interventions for Peripheral Arterial Disease.
    Giagtzidis IT; Kadoglou NP; Mantas G; Spathis A; Papazoglou KO; Karakitsos P; Liapis CD; Karkos CD
    Ann Vasc Surg; 2017 Aug; 43():188-196. PubMed ID: 28288884
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Contemporary cardiovascular risk and secondary preventive drug treatment patterns in peripheral artery disease patients undergoing revascularization.
    Sigvant B; Kragsterman B; Falkenberg M; Hasvold P; Johansson S; Thuresson M; Nordanstig J
    J Vasc Surg; 2016 Oct; 64(4):1009-1017.e3. PubMed ID: 27209402
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alcohol consumption and outcome in stable outpatients with peripheral artery disease.
    Garcia-Diaz AM; Marchena PJ; Toril J; Arnedo G; Muñoz-Torrero JF; Yeste M; Aguilar E; Monreal M;
    J Vasc Surg; 2011 Oct; 54(4):1081-7. PubMed ID: 21684714
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mortality rates and mortality predictors in patients with symptomatic peripheral artery disease stratified according to age and diabetes.
    Mueller T; Hinterreiter F; Luft C; Poelz W; Haltmayer M; Dieplinger B
    J Vasc Surg; 2014 May; 59(5):1291-9. PubMed ID: 24393280
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Functional status as a prognostic factor for primary revascularization for critical limb ischemia.
    Flu HC; Lardenoye JH; Veen EJ; Van Berge Henegouwen DP; Hamming JF
    J Vasc Surg; 2010 Feb; 51(2):360-71.e1. PubMed ID: 20141960
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of soluble TWEAK and CD163/TWEAK ratio on long-term cardiovascular mortality in patients with peripheral arterial disease.
    Urbonaviciene G; Martin-Ventura JL; Lindholt JS; Urbonavicius S; Moreno JA; Egido J; Blanco-Colio LM
    Atherosclerosis; 2011 Dec; 219(2):892-9. PubMed ID: 21962403
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Basement membrane remodeling in skeletal muscles of patients with limb ischemia involves regulation of matrix metalloproteinases and tissue inhibitor of matrix metalloproteinases.
    Baum O; Ganster M; Baumgartner I; Nieselt K; Djonov V
    J Vasc Res; 2007; 44(3):202-13. PubMed ID: 17337906
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of lower limbs' arterial calcification on the prevalence and severity of PAD in patients on hemodialysis.
    Ohtake T; Oka M; Ikee R; Mochida Y; Ishioka K; Moriya H; Hidaka S; Kobayashi S
    J Vasc Surg; 2011 Mar; 53(3):676-83. PubMed ID: 21211928
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum concentrations of L-arginine and L-homoarginine in male patients with intermittent claudication: a cross-sectional and prospective investigation in the CAVASIC Study.
    Vogl L; Pohlhammer J; Meinitzer A; Rantner B; Stadler M; Peric S; Hammerer-Lercher A; Klein-Weigel P; Fraedrich G; Kronenberg F; Kollerits B
    Atherosclerosis; 2015 Apr; 239(2):607-14. PubMed ID: 25746168
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-sensitivity cardiac troponin T in patients with intermittent claudication and its relation with cardiovascular events and all-cause mortality--the CAVASIC Study.
    Pohlhammer J; Kronenberg F; Rantner B; Stadler M; Peric S; Hammerer-Lercher A; Klein-Weigel P; Fraedrich G; Kollerits B
    Atherosclerosis; 2014 Dec; 237(2):711-7. PubMed ID: 25463110
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Matrix metalloproteinases and tissue remodeling in hypertrophic cardiomyopathy.
    Roldán V; Marín F; Gimeno JR; Ruiz-Espejo F; González J; Feliu E; García-Honrubia A; Saura D; de la Morena G; Valdés M; Vicente V
    Am Heart J; 2008 Jul; 156(1):85-91. PubMed ID: 18585501
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patients with unrecognized peripheral arterial disease (PAD) assessed by ankle-brachial index (ABI) present a defined profile of proinflammatory markers compared to healthy subjects.
    Signorelli SS; Anzaldi M; Fiore V; Simili M; Puccia G; Libra M; Malaponte G; Neri S
    Cytokine; 2012 Aug; 59(2):294-8. PubMed ID: 22595645
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of successful percutaneous lower extremity revascularization on cardiovascular outcome in patients with peripheral arterial disease.
    Giugliano G; Di Serafino L; Perrino C; Schiano V; Laurenzano E; Cassese S; De Laurentis M; Schiattarella GG; Brevetti L; Sannino A; Gargiulo G; Franzone A; Indolfi C; Piscione F; Trimarco B; Esposito G
    Int J Cardiol; 2013 Sep; 167(6):2566-71. PubMed ID: 22790191
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Left ventricular ejection fraction is associated with prevalent and incident cardiovascular disease in patients with intermittent claudication - results from the CAVASIC Study.
    Rantner B; Pohlhammer J; Stadler M; Peric S; Hammerer-Lercher A; Klein-Weigel P; Fraedrich G; Kronenberg F; Kollerits B
    Atherosclerosis; 2015 Apr; 239(2):428-35. PubMed ID: 25682043
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasma metalloproteinase-12 and tissue inhibitor of metalloproteinase-1 levels and presence, severity, and outcome of coronary artery disease.
    Jguirim-Souissi I; Jelassi A; Addad F; Hassine M; Najah M; Ben Hamda K; Maatouk F; Ben Farhat M; Bouslema A; Rouis M; Slimane MN
    Am J Cardiol; 2007 Jul; 100(1):23-7. PubMed ID: 17599435
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relation of matrix metalloproteinase-9/tissue inhibitor of metalloproteinase-1 ratio in peripheral circulating CD14+ monocytes to progression of coronary artery disease.
    Brunner S; Kim JO; Methe H
    Am J Cardiol; 2010 Feb; 105(4):429-34. PubMed ID: 20152234
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.